Header Logo

Connection

Mary Rusckowski to Radiopharmaceuticals

This is a "connection" page, showing publications Mary Rusckowski has written about Radiopharmaceuticals.
Connection Strength

2.619
  1. Chen L, Wang Y, Cheng D, Liu X, Dou S, Liu G, Hnatowich DJ, Rusckowski M. (99m)Tc-MORF oligomers specific for bacterial ribosomal RNA as potential specific infection imaging agents. Bioorg Med Chem. 2013 Nov 01; 21(21):6523-30.
    View in: PubMed
    Score: 0.400
  2. Hnatowich DJ, Chang F, Qu T, Rusckowski M. Technetium-99m labeled peptides--an investigation of multiple HPLC peaks. Appl Radiat Isot. 1999 May; 50(5):911-21.
    View in: PubMed
    Score: 0.148
  3. Hnatowich DJ, Qu T, Chang F, Ley AC, Ladner RC, Rusckowski M. Labeling peptides with technetium-99m using a bifunctional chelator of a N-hydroxysuccinimide ester of mercaptoacetyltriglycine. J Nucl Med. 1998 Jan; 39(1):56-64.
    View in: PubMed
    Score: 0.135
  4. Hnatowich DJ, Chang F, Lei K, Qu T, Rusckowski M. The influence of temperature and alkaline pH on the labeling of free and conjugated MAG3 with technetium-99m. Appl Radiat Isot. 1997 May; 48(5):587-94.
    View in: PubMed
    Score: 0.129
  5. Chen L, Cheng D, Liu G, Dou S, Wang Y, Liu X, Liu Y, Rusckowski M. Detection of Klebsiella. Pneumoniae Infection with an Antisense Oligomer Against its Ribosomal RNA. Mol Imaging Biol. 2016 08; 18(4):527-34.
    View in: PubMed
    Score: 0.123
  6. Dou S, Smith M, Wang Y, Rusckowski M, Liu G. Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapy. Cancer Biother Radiopharm. 2013 May; 28(4):335-42.
    View in: PubMed
    Score: 0.097
  7. Liu G, Dou S, Liu Y, Wang Y, Rusckowski M, Hnatowich DJ. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy. Bioconjug Chem. 2011 Dec 21; 22(12):2539-45.
    View in: PubMed
    Score: 0.088
  8. Hoppin J, Orcutt KD, Hesterman JY, Silva MD, Cheng D, Lackas C, Rusckowski M. Assessing antibody pharmacokinetics in mice with in vivo imaging. J Pharmacol Exp Ther. 2011 May; 337(2):350-8.
    View in: PubMed
    Score: 0.084
  9. Cheng D, Rusckowski M, Wang Y, Liu Y, Liu G, Liu X, Hnatowich D. A brief evaluation of tumor imaging in mice with 99mTc-glucarate including a comparison with 18F-FDG. Curr Radiopharm. 2011 Jan; 4(1):5-9.
    View in: PubMed
    Score: 0.083
  10. Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
    View in: PubMed
    Score: 0.082
  11. Liu G, Dou S, Rusckowski M, Greiner D, Hnatowich D. Preparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation. Appl Radiat Isot. 2010 Sep; 68(9):1709-14.
    View in: PubMed
    Score: 0.079
  12. Liu G, Cheng D, Dou S, Chen X, Liang M, Pretorius PH, Rusckowski M, Hnatowich DJ. Replacing 99mTc with 111In improves MORF/cMORF pretargeting by reducing intestinal accumulation. Mol Imaging Biol. 2009 Sep-Oct; 11(5):303-7.
    View in: PubMed
    Score: 0.074
  13. Kleine LG, Solano M, Rusckowski M, Hunt KE, Johnson KL, Kirker-Head CA. Evaluation of technetium Tc 99m-labeled biotin for scintigraphic detection of soft tissue inflammation in horses. Am J Vet Res. 2008 May; 69(5):639-46.
    View in: PubMed
    Score: 0.069
  14. Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ. Investigation of four (99m)Tc-labeled bacteriophages for infection-specific imaging. Nucl Med Biol. 2008 May; 35(4):433-40.
    View in: PubMed
    Score: 0.069
  15. Liu G, Dou S, He J, Yin D, Gupta S, Zhang S, Wang Y, Rusckowski M, Hnatowich DJ. Radiolabeling of MAG3-morpholino oligomers with 188Re at high labeling efficiency and specific radioactivity for tumor pretargeting. Appl Radiat Isot. 2006 Sep; 64(9):971-8.
    View in: PubMed
    Score: 0.061
  16. He J, Liu C, Vanderheyden JL, Liu G, Dou S, Rusckowski M, Hnatowich DJ. Radiolabelling morpholinos with 188Re tricarbonyl provides improved in vitro and in vivo stability to re-oxidation. Nucl Med Commun. 2004 Jul; 25(7):731-6.
    View in: PubMed
    Score: 0.053
  17. Rusckowski M, Gupta S, Liu G, Dou S, Hnatowich DJ. Investigations of a (99m)Tc-labeled bacteriophage as a potential infection-specific imaging agent. J Nucl Med. 2004 Jul; 45(7):1201-8.
    View in: PubMed
    Score: 0.053
  18. Liu CB, Liu GZ, Liu N, Zhang YM, He J, Rusckowski M, Hnatowich DJ. Radiolabeling morpholinos with 90Y, 111In, 188Re and 99mTc. Nucl Med Biol. 2003 Feb; 30(2):207-14.
    View in: PubMed
    Score: 0.048
  19. Liu G, Zhang S, He J, Zhu Z, Rusckowski M, Hnatowich DJ. Improving the labeling of S-acetyl NHS-MAG(3)-conjugated morpholino oligomers. Bioconjug Chem. 2002 Jul-Aug; 13(4):893-7.
    View in: PubMed
    Score: 0.046
  20. Su ZF, Liu G, Gupta S, Zhu Z, Rusckowski M, Hnatowich DJ. In vitro and in vivo evaluation of a Technetium-99m-labeled cyclic RGD peptide as a specific marker of alpha(V)beta(3) integrin for tumor imaging. Bioconjug Chem. 2002 May-Jun; 13(3):561-70.
    View in: PubMed
    Score: 0.046
  21. Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med. 2002 Mar; 43(3):384-91.
    View in: PubMed
    Score: 0.045
  22. Zhang YM, Wang Y, Liu N, Zhu ZH, Rusckowski M, Hnatowich DJ. In vitro investigations of tumor targeting with (99m)Tc-labeled antisense DNA. J Nucl Med. 2001 Nov; 42(11):1660-9.
    View in: PubMed
    Score: 0.044
  23. Mang'era KO, Liu G, Yi W, Zhang Y, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Initial investigations of 99mTc-labeled morpholinos for radiopharmaceutical applications. Eur J Nucl Med. 2001 Nov; 28(11):1682-9.
    View in: PubMed
    Score: 0.044
  24. Zhang YM, Rusckowski M, Liu N, Liu C, Hnatowich DJ. Cationic liposomes enhance cellular/nuclear localization of 99mTc-antisense oligonucleotides in target tumor cells. Cancer Biother Radiopharm. 2001 Oct; 16(5):411-9.
    View in: PubMed
    Score: 0.044
  25. Wang Y, Chang F, Zhang Y, Liu N, Liu G, Gupta S, Rusckowski M, Hnatowich DJ. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjug Chem. 2001 Sep-Oct; 12(5):807-16.
    View in: PubMed
    Score: 0.044
  26. Qu T, Wang Y, Zhu Z, Rusckowski M, Hnatowich DJ. Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm. Nucl Med Commun. 2001 Feb; 22(2):203-15.
    View in: PubMed
    Score: 0.042
  27. Rusckowski M, Qu T, Pullman J, Marcel R, Ley AC, Ladner RC, Hnatowich DJ. Inflammation and infection imaging with a 99mTc-neutrophil elastase inhibitor in monkeys. J Nucl Med. 2000 Feb; 41(2):363-74.
    View in: PubMed
    Score: 0.039
  28. Chang F, Qu T, Rusckowski M, Hnatowich DJ. NHS-MAS3: a bifunctional chelator alternative to NHS-MAG3. Appl Radiat Isot. 1999 Apr; 50(4):723-32.
    View in: PubMed
    Score: 0.037
  29. Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, Egholm M, Hnatowich DJ. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med. 1997 Jun; 38(6):907-13.
    View in: PubMed
    Score: 0.032
  30. Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging. 2010 Jun; 54(3):333-40.
    View in: PubMed
    Score: 0.019
  31. Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer. 2009 Nov; 45(17):3098-103.
    View in: PubMed
    Score: 0.019
  32. Liu X, Wang Y, Nakamura K, Kawauchi S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. Auger radiation-induced, antisense-mediated cytotoxicity of tumor cells using a 3-component streptavidin-delivery nanoparticle with 111In. J Nucl Med. 2009 Apr; 50(4):582-90.
    View in: PubMed
    Score: 0.018
  33. Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
    View in: PubMed
    Score: 0.017
  34. Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF. Eur J Nucl Med Mol Imaging. 2008 Feb; 35(2):272-80.
    View in: PubMed
    Score: 0.017
  35. Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice. Eur J Nucl Med Mol Imaging. 2007 Feb; 34(2):237-46.
    View in: PubMed
    Score: 0.016
  36. He J, Rusckowski M, Wang Y, Dou S, Liu X, Zhang S, Liu G, Hnatowich DJ. Optical pretargeting of tumor with fluorescent MORF oligomers. Mol Imaging Biol. 2007 Jan-Feb; 9(1):17-23.
    View in: PubMed
    Score: 0.016
  37. Wang Y, Liu X, Zhang Y, Liu G, Rusckowski M, Hnatowich DJ. Nonspecific cellular accumulation of 99mTc-labeled oligonucleotides in culture is influenced by their guanine content. Nucl Med Biol. 2007 Jan; 34(1):47-54.
    View in: PubMed
    Score: 0.016
  38. Zhang YM, Tung CH, He J, Liu N, Yanachkov I, Liu G, Rusckowski M, Vanderheyden JL. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Nucl Med Biol. 2006 Feb; 33(2):263-9.
    View in: PubMed
    Score: 0.015
  39. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging. 2005 Sep; 32(9):1115-23.
    View in: PubMed
    Score: 0.014
  40. Zhang Y, He J, Liu G, Venderheyden JL, Gupta S, Rusckowski M, Hnatowich DJ. Initial observations of 99mTc labelled locked nucleic acids for antisense targeting. Nucl Med Commun. 2004 Nov; 25(11):1113-8.
    View in: PubMed
    Score: 0.014
  41. He J, Liu G, Gupta S, Zhang Y, Rusckowski M, Hnatowich DJ. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J Nucl Med. 2004 Jun; 45(6):1087-95.
    View in: PubMed
    Score: 0.013
  42. Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, Hnatowich DJ. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake. Eur J Nucl Med Mol Imaging. 2004 Mar; 31(3):417-24.
    View in: PubMed
    Score: 0.013
  43. He J, Liu G, Zhang S, Rusckowski M, Hnatowich DJ. Pharmacokinetics in mice of four oligomer-conjugated polymers for amplification targeting. Cancer Biother Radiopharm. 2003 Dec; 18(6):941-7.
    View in: PubMed
    Score: 0.013
  44. He J, Liu G, Zhang S, Vanderheyden JL, Liu N, Liu C, Zhang Y, Gupta S, Rusckowski M, Hnatowich DJ. A comparison of in vitro and in vivo stability in mice of two morpholino duplexes differing in chain length. Bioconjug Chem. 2003 Sep-Oct; 14(5):1018-23.
    View in: PubMed
    Score: 0.013
  45. Ferro-Flores G, Arteaga de Murphy C, Pedraza-L?pez M, Mel?ndez-Alafort L, Zhang YM, Rusckowski M, Hnatowich DJ. In vitro and in vivo assessment of 99mTc-UBI specificity for bacteria. Nucl Med Biol. 2003 Aug; 30(6):597-603.
    View in: PubMed
    Score: 0.012
  46. Liu G, Liu C, Zhang S, He J, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Investigations of 99mTc morpholino pretargeting in mice. Nucl Med Commun. 2003 Jun; 24(6):697-705.
    View in: PubMed
    Score: 0.012
  47. Su ZF, He J, Rusckowski M, Hnatowich DJ. In vitro cell studies of technetium-99m labeled RGD-HYNIC peptide, a comparison of tricine and EDDA as co-ligands. Nucl Med Biol. 2003 Feb; 30(2):141-9.
    View in: PubMed
    Score: 0.012
  48. Liu G, Zhang S, He J, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice. Q J Nucl Med. 2002 Sep; 46(3):233-43.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.